Standard Biotools Inc - SIC # 3826 - LABORATORY ANALYTICAL INSTRUMENTS

Ticker Exchange SIC # Website Latest Ticker
LAB Nasdaq 3826 https://www.fluidigm.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Standard Biotools Inc

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mar 22nd, 2023 12:30 pm
Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors - Mar 15th, 2023 12:30 pm
Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum - Mar 14th, 2023 12:30 pm
Standard BioTools to Present at 43rd Annual Cowen Health Care Conference - Mar 1st, 2023 9:05 pm
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 21st, 2023 1:30 pm
Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript - Feb 17th, 2023 11:43 pm
How a Peninsula biotech tools company looks to corral 'one-trick ponies' - Feb 15th, 2023 11:01 pm
Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook - Feb 14th, 2023 9:05 pm
The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable - Feb 3rd, 2023 10:30 am
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results - Jan 31st, 2023 1:30 pm
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update - Jan 9th, 2023 1:30 pm
Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer - Jan 3rd, 2023 1:30 pm
Standard BioTools Inc. (NASDAQ:LAB) institutional owners may be pleased with recent gains after 64% loss over the past year - Dec 24th, 2022 1:01 pm
Standard BioTools Authorizes up to $20 Million of Share Repurchases - Nov 28th, 2022 1:30 pm
Standard BioTools Third Quarter 2022 Earnings: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) - Nov 11th, 2022 10:02 am
Standard BioTools Announces Third Quarter 2022 Financial Results - Nov 8th, 2022 9:05 pm
Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems - Nov 7th, 2022 9:05 pm
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results - Oct 25th, 2022 12:30 pm
Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China - Oct 13th, 2022 12:30 pm
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform - Oct 6th, 2022 12:30 pm